Serum prolactin levels are significantly greater among hypertensive patients receiving reserpine as compared to levels six weeks after discontinuing the treatment (P <.005). This association between regular, longterm reserpine use and greater prolactin levels may be clinically significant, since an increased incidence of breast cancer has been reported among hypertensive patients receiving reserpine.
|Original language||English (US)|
|Number of pages||2|
|Journal||JAMA: The Journal of the American Medical Association|
|State||Published - May 24 1976|
All Science Journal Classification (ASJC) codes